Dr. Kauffman joined Verastem Oncology in December 2025 as President of Development after serving as the Company’s Lead Director of Verastem’s Board of Directors since June 2016. Dr. Kauffman has a deep understanding of the Company’s strategy, clinical development plans, and operations.
 

Previously, Dr. Kauffman served as the Chief Executive Officer of Nereid Therapeutics. He was co-founder and Chief Executive Officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial stage organization and the global approvals of XPOVIO®. Prior to co-founding Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharma, where he led the development of Kyprolis® following the Onyx acquisition of Proteolix Inc., where he served as a board member and then Chief Medical Officer. Previously, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals. He also held a number of senior positions at Millennium Predictive Medicine and Biogen Inc.
 

Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School, trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and in Rheumatology at Massachusetts General Hospital, and is board certified in Internal Medicine.